Stay Updated with the Latest InSilico Medicine Cayman TopCo 3696.HK News in Real Time
Find 3696.HK news now at Meyka AI. Stay informed with the latest InSilico Medicine Cayman TopCo stocks updates, including price news, market analysis, and expert insights.
Cuba Approves 176 Free-Market Reforms in Historic Economic Shift, June 20
Cuba approves 176 free-market reforms to open economy and attract investment amid US embargo. Most significant economic shift since 1959 revolution.
Shenzhen Metro Line 13 Phase 2 Opens June 30, Cuts Travel Time to 45 Minutes
Shenzhen Metro Line 13 Phase 2 opens June 30 with 11 stations spanning 19.25 km across Guangming, Baoan, and Nanshan districts.
Idorsia Stock Surges 24% on Debt Refinancing Deal, June 19
Idorsia stock surges 24% to 5.78 CHF after refinancing debt and extending liquidity to 2028. Swiss biotech advances insomnia drug development.
Alembic Pharmaceuticals Shares Jump 3% After US FDA Tentatively Approves Larotrectinib Capsules
Alembic Pharmaceuticals shares rose nearly 3% in trading after the company announced that the US Food and Drug Administration (FDA) granted tentative approval for its Larotrectinib capsules. The development marks a positive milestone for the Indian pharmaceutical company as it continues to expand its presence in the regulated US market. The announcement triggered strong investor…
Air Canada Captain Charged After Flying 900+ Flights Without License
Geoffrey Wall charged with fraud after flying 900+ Air Canada flights without required airline transport pilot license in 17-year deception.
Concord Biotech Shares Jump 5.9% After US FDA Approves Tofacitinib Arthritis Drug
Shares of Concord Biotech saw strong buying interest after a key global development. The stock rose around 5.9% in recent trading sessions after news of a US FDA approval related to its Tofacitinib-based arthritis drug. The trigger is important. The US Food and Drug Administration (FDA) approval opens doors to the world’s largest pharmaceutical market….
GSK to Buy Nuvalent for $10.6 Billion, Paying $124 Per Share in All-Cash Deal
GSK has made a major move in the global pharmaceutical industry. The company has agreed to acquire Nuvalent for $10.6 billion in an all-cash deal. The offer price is $124 per share, which is about a 40% premium compared to the last closing price of Nuvalent. This is not a small deal. It is one…
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…
Eli Lilly Stock (LLY) Jumps 4% to $1,131.42 USD as Retatrutide Cuts Sleep Apnea by 60% in Phase 3 Trial
Eli Lilly stock gained approximately 4 percent and climbed to $1,131.42 USD after the company announced promising Phase 3 clinical trial results for Retatrutide. The experimental drug demonstrated a remarkable ability to reduce obstructive sleep apnea severity by nearly 60 percent, generating excitement among investors and healthcare professionals. The announcement strengthened confidence in Eli Lilly’s…